N4 Pharma PLC Result of AGM (3304T)
24 Marzo 2021 - 4:45AM
UK Regulatory
TIDMN4P
RNS Number : 3304T
N4 Pharma PLC
24 March 2021
24 March 2021
N4 Pharma plc
("N4 Pharma" or the "Company")
Result of Annual General Meeting
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to announce that at its annual general
meeting ("AGM"), held earlier today, all resolutions were duly
passed. The results of the proxy voting for the AGM are set out
below.
Resolution (*Special Total Shares Shares %
Resolution) Voted
For Against For Against
------------- ----------- -------- ------ --------
1. To receive
the annual report
and audited accounts
for the year
ended 31 December
2020 20,289,075 20,222,189 66,886 99.67 0.33
------------- ----------- -------- ------ --------
2. To re-elect
Chris Britten
as a Director
of the Company 20,286,756 20,153,341 133,415 99.34 0.66
------------- ----------- -------- ------ --------
3. To re-elect
Luke Cairns as
a Director of
the Company 20,286,756 20,194,827 91,929 99.55 0.45
------------- ----------- -------- ------ --------
4. To re-elect
John Chiplin
as a Director
of the Company 20,286,756 20,209,370 77,386 99.62 0.38
------------- ----------- -------- ------ --------
5. To re-appoint
Saffery Champness
LLP as auditor
to the company
and authorise
the directors
to determine
their remuneration 20,219,901 20,134,176 85,725 99.58 0.42
------------- ----------- -------- ------ --------
6. To authorise
the Directors
to allot shares 20,283,475 20,101,362 182,113 99.10 0.90
------------- ----------- -------- ------ --------
7* . To disapply
pre-emption rights 20,250,090 20,123,051 127,039 99.37 0.63
------------- ----------- -------- ------ --------
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker/Zoe Alexander
IFC Advisory Ltd Tel: +44(0)20 3934
Financial PR 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGBGGDXBSDDGBS
(END) Dow Jones Newswires
March 24, 2021 06:45 ET (10:45 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024